BG002
Venous leg ulcer
Phase 3Active
Key Facts
About Tissue Repair
Australian‑based biotech leveraging beta‑glucan immunomodulation to treat wounds and enhance aesthetic recovery.
View full company profileTherapeutic Areas
Other Venous leg ulcer Drugs
| Drug | Company | Phase |
|---|---|---|
| BG003 | Tissue Repair | Phase 3 |